ATX-LPA Axis Induces Expression of OPN in Hepatic Cancer Cell SMMC7721

Anatomical Record

Volumn 294, Issue 3, 2011, Pages 406-411

  Zhang, Rihua ^a   Zhang, Zhihong ^a   Pan, Xiaolin ^a   Huang, Xiayue ^a   Huang, Zuhu ^a   Zhang, Guoxin ^a  

^a THE FIRST AFFILIATED HOSPITAL OF NANJING MEDICAL UNIVERSITY   (China)

Author keywords

ATX LPA axis; Autotaxin; Lysophosphatidic acid; Lysophosphatidylcholine; Osteopontin

Indexed keywords

AUTOTAXIN; LYSOPHOSPHATIDIC ACID; MESSENGER RNA; OSTEOPONTIN; PHOSPHATIDYLINOSITOL 3 KINASE INHIBITOR; PROTEIN KINASE B;

ARTICLE; CANCER CELL; CELL ASSAY; CELL MIGRATION; COMPARATIVE STUDY; CONTROLLED STUDY; HUMAN; HUMAN CELL; IMMUNOCYTOCHEMISTRY; LIVER CANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TRANSWELL MIGRATION ASSAY; UPREGULATION; WESTERN BLOTTING;

BLOTTING, WESTERN; CELL MOVEMENT; HUMANS; LIVER NEOPLASMS; LYSOPHOSPHOLIPIDS; MULTIENZYME COMPLEXES; OSTEOPONTIN; PHOSPHATIDYLINOSITOL 3-KINASE; PHOSPHODIESTERASE I; PROTO-ONCOGENE PROTEINS C-AKT; PYROPHOSPHATASES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION; TUMOR CELLS, CULTURED;

EID: 79951767028     PISSN: 19328486     EISSN: 19328494     Source Type: Journal    
DOI: 10.1002/ar.21324     Document Type: Article

References (30)

1. Chae S, Jun HO, Lee EG, Yang SJ, Lee DC, Jung JK, Park KC, Yeom YI, Kim KW. 2009. Osteopontin splice variants differentially modulate the migratory activity of hepatocellular carcinoma cell lines. Int J Oncol 35: 1409-1416.
2. Chen RX, Xue TC, Ye SL, Sun RX, Zhao Y, Tang ZY. 2007. Osteopontin promotes the malignant phenotypes of human hepatocellular carcinoma cell line SMMC-7721. Zhonghua Gan Zang Bing Za Zhi 15: 37-40.
3. Cui BK, Zhang CQ, Zhang Y, Yuan YF, Zhang YQ, Shi M, Chen MS, Li SP, Li JQ. 2006. Osteopontin as a potential biomarker of metastasis and recurrence for hepatocellular carcinoma. Ai Zheng 25: 876-879.
4. Fang X, Schummer M, Mao M, Yu S, Tabassam FH, Swaby R, Hasegawa Y, Tanyi JL, LaPushin R, Eder A, Jaffe R, Erickson J, Mills GB. 2002. Lysophosphatidic acid is a bioactive mediator in ovarian cancer. Biochim Biophys Acta 1582: 257-264.
5. Gong M, Lu Z, Fang G, Bi J, Xue X. 2008. A small interfering RNA targeting osteopontin as gastric cancer therapeutics. Cancer Lett 272: 148-159.
6. Higashiyama M, Ito T, Tanaka E, Shimada Y. 2007. Prognostic significance of osteopontin expression in human gastric carcinoma. Ann Surg Oncol 14: 3419-3427.
7. Horita Y, Ohashi K, Mukai M, Inoue M, Mizuno K. 2008. Suppression of the invasive capacity of rat ascites hepatoma cells by knockdown of Slingshot or LIM kinase. J Biol Chem 283: 6013-6021.
8. Johnston NI, Gunasekharan VK, Ravindranath A, O'Connell C, Johnston PG, El-Tanani MK. 2008. Osteopontin as a target for cancer therapy. Front Biosci 13: 4361-4372.
9. Kanda H, Newton R, Klein R, Morita Y, Gunn MD, Rosen SD. 2008. Autotaxin, an ectoenzyme that produces lysophosphatidic acid, promotes the entry of lymphocytes into secondary lymphoid organs. Nat Immunol 9: 415-423.
10. Kehlen A, Englert N, Seifert A, Klonisch T, Dralle H, Langner J, Hoang-Vu C. 2004. Expression, regulation and function of autotaxin in thyroid carcinomas. Int J Cancer 109: 833-838.
11. Kim J, Ki SS, Lee SD, Han CJ, Kim YC, Park SH, Cho SY, Hong YJ, Park HY, Lee M, Jung HH, Lee KH, Jeong SH. 2006. Elevated plasma osteopontin levels in patients with hepatocellular carcinoma. Am J Gastroenterol 101: 2051-2059.
12. Kim MH, Park JS, Chang HJ, Baek MK, Kim HR, Shin BA, Ahn BW, Jung YD. 2008a. Lysophosphatidic acid promotes cell invasion by up-regulating the urokinase-type plasminogen activator receptor in human gastric cancer cells. J Cell Biochem 104: 1102-1112.
13. Kim EK, Yun SJ, Do KH, Kim MS, Cho M, Suh DS, Kim CD, Kim JH, Birnbaum MJ, Bae SS. 2008b. Lysophosphatidic acid induces cell migration through the selective activation of Akt1. Exp Mol Med 40: 445-452.
14. Kim SH, Chung YH, Yang SH, Kim JA, Jang MK, Kim SE, Lee D, Lee SH, Lee D, Kim KM, Lim YS, Lee HC, Lee YS, Suh DJ. 2009. Prognostic value of serum osteopontin in hepatocellular carcinoma patients treated with transarterial chemoembolization. Korean J Hepatol 15: 320-330.
15. Liu YB, Kharode Y, Bodine PV, Yaworsky PJ, Robinson JA, Billiard J. 2010. LPA induces osteoblast differentiation through interplay of two receptors: LPA1 and LPA4. J Cell Biochem 109: 794-800.
16. Moolenaar WH, van Meeteren LA, Giepmans BN. 2004. The ins and outs of lysophosphatidic acid signaling. Bioessays 26: 870-881.
17. Pua TL, Wang FQ, Fishman DA. 2009. Roles of LPA in ovarian cancer development and progression. Future Oncol l5: 1659-1673.
18. Quiles-Perez R, Muñoz-Gámez JA, Ruiz-Extremera A, O'Valle F, Sanjuán-Nuñez L, Martín-Alvarez AB, Martín-Oliva D, Caballero T, Muñoz de Rueda P, León J, Gonzalez R, Muntané J, Oliver FJ, Salmerón J. 2010. Inhibition of poly adenosine diphosphate-ribose polymerase decreases hepatocellular carcinoma growth by modulation of tumor-related gene expression. Hepatology 51: 255-266.
19. Rodrigues LR, Teixeira JA, Schmitt FL, Paulsson M, Lindmark-Mänsson H. 2007. The role of osteopontin in tumor progression and metastasis in breast cancer. Cancer Epidemiol Biomarkers Prev 16: 1087-1097.
20. Sako A, Kitayama J, Shida D, Suzuki R, Sakai T, Ohta H, Nagawa H. 2006. Lysophosphatidic acid (LPA)-induced vascular endothelial growth factor (VEGF) by mesothelial cells and quantification of host-derived VEGF in malignant ascites. J Surg Res 130: 94-101.
21. Song G, Ming Y, Mao Y, Bao S, Ouyang G. 2008. Osteopontin prevents curcumin-induced apoptosis and promotes survival through Akt activation via alpha v beta 3 integrins in human gastric cancer cells. Exp Biol Med 233: 1537-1545.
22. Takafuji V, Forgues M, Unsworth E, Goldsmith P, Wang XW. 2007. An osteopontin fragment is essential for tumor cell invasion in hepatocellular carcinoma. Oncogene 26: 6361-6371.
23. Umezu-Goto M, Kishi Y, Taira A, Hama K, Dohmae N, Takio K, Yamori T, Mills GB, Inoue K, Aoki J, Arai H. 2002. Autotaxin has lysophospholipase D activity leading to tumor cell growth and motility by lysophosphatidic acid production. J Cell Biol 158: 227-233.
24. Van Meeteren LA, Moolenaar WH. 2007. Regulation and biological activities of the autotoxin-LPA axis. Prog Lipid Res 46: 145-160.
25. Wang FQ, Ariztia EV, Boyd LR, Horton FR, Smicun Y, Hetherington JA, Smith PJ, Fishman DA. 2010. Lysophosphatidic acid (LPA) effects on endometrial carcinoma in vitro proliferation, invasion, and matrix metalloproteinase activity. Gynecol Oncol 117: 88-95.
26. Xie Y, Meier KE. 2004. Lysophospholipase D and its role in LPA production. Cell Signal 16: 975-981.
27. Yang SY, Lee J, Park CG, Kim S, Hong S, Chung HC, Min SK, Han JW, Lee HW, Lee HY. 2002. Expression of autotaxin (NPP-2) is closely linked to invasiveness of breast cancer cells. Clin Exp Metastasis 19: 603-608.
28. Yoo KH, Thornhill BA, Forbes MS, Coleman CM, Marcinko ES, Liaw L, Chevalier RL. 2006. Osteopontin regulates renal apoptosis and interstitial fibrosis in neonatal chronic unilateral ureteral obstruction. Kidney Int 70: 1735-1741.
29. Yu S, Murph MM, Lu Y, Liu S, Hall HS, Liu J, Stephens C, Fang X, Mills GB. 2008. Lysophosphatidic acid receptors determine tumorigenicity and aggressiveness of ovarian cancer cells. J Natl Cancer Inst 100: 1630-1642.
30. Zhang GX, Zhao ZQ, Lin XW. 2003. EGF/PI3K signaling pathway regulates the expression of osteopontin in liver cancer HepG2 cells. Zhonghua Yi Xue Za Zhi 83: 1980-1983.